Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and rucaparib (Rubraca; Pharma&), which provide therapeutic options for ovarian cancer patients, including those with HRD and deleterious BRCA mutations. The folate receptor-alpha (FRα) protein is now a target in the treatment of advanced disease; mirvetuximab soravtansine (Elahere; ImmunoGen / AbbVie) entered the U.S. and European markets as the first ADC targeting patients with high FRα-expressing tumors (TPS ≥ 75%). The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with distinct mechanisms of action, including immune checkpoint inhibitors and ADCs, could further diversify treatment options if successful in late-phase studies.

Questions answered

• What is the size of clinically and commercially relevant drug-treatable ovarian cancer populations, and how will drug-treatment rates change (if at all) over time?
• What is the current treatment landscape for ovarian cancer? What are interviewed experts’ opinions on current therapies?
• What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?
• What are the main drivers of, and constraints in, the treatment of ovarian cancer, and how will this market evolve over the forecast period?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research

Epidemiology: Diagnosed incidence by country and disease stage; clinically and market-relevant drug-treatable populations

Forecast: 10-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.